Targeting “messenger RNAs” may correct mutations in human mitochondrial DNA, experts at UCLA say. Currently, there is no way to successfully repair or compensate for these mutations in the human mitochondrial genome, implicated in neuromuscular diseases, metabolic defects and aging. The findings could lead to a form of gene therapy.